Skip directly to page options Skip directly to A-Z link

Volume 28, Number 6—June 2022

Research

Risk Prediction Score for Pediatric Patients with Suspected Ebola Virus Disease

Alicia E. Genisca1Comments to Author , Tzu-Chun Chu1, Lawrence Huang, Monique Gainey, Moyinoluwa Adeniji, Eta N. Mbong, Stephen B. Kennedy, Razia Laghari, Fiston Nganga, Rigo F. Muhayangabo, Himanshu Vaishnav, Shiromi M. Perera, Andrés Colubri2, Adam C. Levine2, and Ian C. Michelow23Comments to Author 
Author affiliations: Brown Emergency Medicine, Providence, Rhode Island, USA (A.E. Genisca, H. Vaishnav, A.C. Levine); Alpert Medical School of Brown University, Providence (A.E. Genisca, A.C. Levine, I.C. Michelow); University of Georgia, Athens, Georgia, USA (T.C. Chu); Brown University, Providence (L. Huang, M. Adeniji); Rhode Island Hospital, Providence (M. Gainey); International Medical Corps, Goma, Democratic Republic of the Congo (E.N. Mbong, R. Laghari, F. Nganga, R.F. Muhayangabo); Ministry of Health, Monrovia, Liberia (S.B. Kennedy); International Medical Corps, Washington, DC, USA (S.M. Perera); University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA (A. Colubri)

Main Article

Table 4

Demographic and clinical characteristics of patients, by EVD status at triage, in Democratic Republic of the Congo, December 2018–December 2019*

Characteristic† Overall, no. (%), n = 1,336 EVD positive, no (%), n = 84 (6%) EVD negative, no. (%), n = 1,252 (94%) OR (95% CI) p value
Sex
M 690 (52) 32 (38) 658 (53) 0.56 (0.35–0.87) 0.01
F
 646 (48)
 52 (62)
 594 (47)
 Referent
Signs/symptoms
Fever 818 (61) 72 (86) 746 (60) 4.07 (2.27–7.96) <0.001
Headache 700 (52) 47 (56) 653 (52) 1.17 (0.75–1.83) 0.50
Breathlessness 93 (7.0) 13 (15) 80 (6.4) 2.68 (1.37–4.90) 0.002
Bone/muscle pain 116 (8.7) 16 (19) 100 (8.0) 2.71 (1.47–4.74) <0.001
Asthenia 960 (72) 62 (74) 898 (72) 1.11 (0.68–1.87) 0.68
Abdominal pain 458 (34) 34 (40) 424 (34) 1.33 (0.84–2.08) 0.22
Hiccups 16 (1.2) 1 (1.2) 15 (1.2) 0.99 (0.05–4.99) >0.99
Any bleeding 99 (7.4) 21 (25) 78 (6.2) 5.02 (2.86–8.54) <0.001
GI symptoms
 1,026 (77)
 84 (100)
 942 (75)
 55.7 (3.44–900)
 0.005
Ebola contact
Yes 191 (14) 54 (64) 137 (11) 5.40 (3.03–10.1) <0.001
No known 910 (68) 14 (17) 896 (71) 0.21 (0.10–0.45)
No 235 (18) 16 (19) 219 (17) Referent

*Age, y, mean (interquartile range): overall, 7 (2–11); EVD positive, 5 (1.4–13); EVD negative, 6 (2.5–11); OR 1.00 (95% CI 0.96–1.04); p = 0.96. EVD, Ebola virus disease; GI, gastrointestinal; OR, odds ratio. †Malaria was not reported for this cohort because rapid diagnostic tests for malaria were not conducted for all patients at the EVD treatment centers.

Main Article

1These authors contributed equally to this article.

2These authors contributed equally to this article.

3Current affiliation: Pediatric Infectious Diseases & Immunology, Connecticut Children’s Medical Center, Hartford, Connecticut, USA.

Page created: April 11, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external